nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—MAPK14—liver cancer	0.556	0.907	CbGaD
Celecoxib—ABCC4—Sorafenib—liver cancer	0.0707	0.595	CbGbCtD
Celecoxib—ALB—liver cancer	0.0566	0.0924	CbGaD
Celecoxib—CYP2C9—Sorafenib—liver cancer	0.0141	0.119	CbGbCtD
Celecoxib—CYP2D6—Sorafenib—liver cancer	0.0129	0.109	CbGbCtD
Celecoxib—CYP3A4—Sorafenib—liver cancer	0.00821	0.0692	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—liver cancer	0.00784	0.066	CbGbCtD
Celecoxib—ORM1—bile—liver cancer	0.00518	0.221	CbGeAlD
Celecoxib—CYP3A4—Doxorubicin—liver cancer	0.00498	0.042	CbGbCtD
Celecoxib—Etoricoxib—MAPK14—liver cancer	0.00409	0.844	CrCbGaD
Celecoxib—PDPK1—embryo—liver cancer	0.00283	0.121	CbGeAlD
Celecoxib—CA9—gall bladder—liver cancer	0.00245	0.105	CbGeAlD
Celecoxib—MAPK14—embryo—liver cancer	0.00151	0.0646	CbGeAlD
Celecoxib—ORM1—gall bladder—liver cancer	0.00144	0.0613	CbGeAlD
Celecoxib—PDPK1—liver—liver cancer	0.00131	0.0559	CbGeAlD
Celecoxib—ALB—gall bladder—liver cancer	0.00126	0.0538	CbGeAlD
Celecoxib—CA5A—liver—liver cancer	0.00123	0.0524	CbGeAlD
Celecoxib—CA2—gall bladder—liver cancer	0.00093	0.0397	CbGeAlD
Celecoxib—Etoricoxib—CYP2E1—liver cancer	0.000757	0.156	CrCbGaD
Celecoxib—MAPK14—liver—liver cancer	0.0007	0.0299	CbGeAlD
Celecoxib—PTGS2—gall bladder—liver cancer	0.000686	0.0293	CbGeAlD
Celecoxib—CA14—liver—liver cancer	0.000681	0.0291	CbGeAlD
Celecoxib—CA2—embryo—liver cancer	0.000589	0.0252	CbGeAlD
Celecoxib—PTGS2—embryo—liver cancer	0.000435	0.0186	CbGeAlD
Celecoxib—ORM1—liver—liver cancer	0.000421	0.018	CbGeAlD
Celecoxib—ALB—liver—liver cancer	0.000369	0.0158	CbGeAlD
Celecoxib—ABCC4—liver—liver cancer	0.000358	0.0153	CbGeAlD
Celecoxib—CA2—liver—liver cancer	0.000273	0.0116	CbGeAlD
Celecoxib—CYP2C9—liver—liver cancer	0.000231	0.00985	CbGeAlD
Celecoxib—PTGS2—liver—liver cancer	0.000201	0.00859	CbGeAlD
Celecoxib—CYP3A4—liver—liver cancer	0.000176	0.00751	CbGeAlD
Celecoxib—CYP2D6—liver—liver cancer	0.000173	0.00739	CbGeAlD
Celecoxib—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000159	0.00146	CcSEcCtD
Celecoxib—Asthenia—Sorafenib—liver cancer	0.000159	0.00146	CcSEcCtD
Celecoxib—Hypoglycaemia—Doxorubicin—liver cancer	0.000158	0.00145	CcSEcCtD
Celecoxib—Cardiac failure—Doxorubicin—liver cancer	0.000158	0.00145	CcSEcCtD
Celecoxib—Cerebrovascular accident—Doxorubicin—liver cancer	0.000157	0.00145	CcSEcCtD
Celecoxib—Pruritus—Sorafenib—liver cancer	0.000157	0.00144	CcSEcCtD
Celecoxib—Ataxia—Epirubicin—liver cancer	0.000157	0.00144	CcSEcCtD
Celecoxib—Blood creatinine increased—Epirubicin—liver cancer	0.000156	0.00143	CcSEcCtD
Celecoxib—Hyponatraemia—Doxorubicin—liver cancer	0.000155	0.00142	CcSEcCtD
Celecoxib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000154	0.00142	CcSEcCtD
Celecoxib—Osteoarthritis—Doxorubicin—liver cancer	0.000154	0.00142	CcSEcCtD
Celecoxib—Liver function test abnormal—Epirubicin—liver cancer	0.000154	0.00141	CcSEcCtD
Celecoxib—Dry skin—Epirubicin—liver cancer	0.000153	0.0014	CcSEcCtD
Celecoxib—Abdominal pain upper—Epirubicin—liver cancer	0.000152	0.0014	CcSEcCtD
Celecoxib—Migraine—Doxorubicin—liver cancer	0.000152	0.00139	CcSEcCtD
Celecoxib—Hypokalaemia—Epirubicin—liver cancer	0.000152	0.00139	CcSEcCtD
Celecoxib—Diarrhoea—Sorafenib—liver cancer	0.000152	0.00139	CcSEcCtD
Celecoxib—Breast disorder—Epirubicin—liver cancer	0.000151	0.00138	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00015	0.00138	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00015	0.00138	CcSEcCtD
Celecoxib—Nasopharyngitis—Epirubicin—liver cancer	0.000149	0.00137	CcSEcCtD
Celecoxib—Face oedema—Doxorubicin—liver cancer	0.000149	0.00137	CcSEcCtD
Celecoxib—Gastritis—Epirubicin—liver cancer	0.000147	0.00136	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000147	0.00135	CcSEcCtD
Celecoxib—Dizziness—Sorafenib—liver cancer	0.000146	0.00135	CcSEcCtD
Celecoxib—Ataxia—Doxorubicin—liver cancer	0.000145	0.00133	CcSEcCtD
Celecoxib—Blood creatinine increased—Doxorubicin—liver cancer	0.000144	0.00133	CcSEcCtD
Celecoxib—Dysphagia—Epirubicin—liver cancer	0.000144	0.00132	CcSEcCtD
Celecoxib—Eosinophilia—Epirubicin—liver cancer	0.000143	0.00131	CcSEcCtD
Celecoxib—Liver function test abnormal—Doxorubicin—liver cancer	0.000142	0.00131	CcSEcCtD
Celecoxib—Dry skin—Doxorubicin—liver cancer	0.000141	0.0013	CcSEcCtD
Celecoxib—Pancreatitis—Epirubicin—liver cancer	0.000141	0.0013	CcSEcCtD
Celecoxib—Vomiting—Sorafenib—liver cancer	0.000141	0.00129	CcSEcCtD
Celecoxib—Abdominal pain upper—Doxorubicin—liver cancer	0.000141	0.00129	CcSEcCtD
Celecoxib—Hypokalaemia—Doxorubicin—liver cancer	0.00014	0.00129	CcSEcCtD
Celecoxib—Angina pectoris—Epirubicin—liver cancer	0.00014	0.00129	CcSEcCtD
Celecoxib—Rash—Sorafenib—liver cancer	0.00014	0.00128	CcSEcCtD
Celecoxib—Dermatitis—Sorafenib—liver cancer	0.00014	0.00128	CcSEcCtD
Celecoxib—Breast disorder—Doxorubicin—liver cancer	0.000139	0.00128	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000139	0.00128	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000139	0.00128	CcSEcCtD
Celecoxib—Headache—Sorafenib—liver cancer	0.000139	0.00128	CcSEcCtD
Celecoxib—Bronchitis—Epirubicin—liver cancer	0.000138	0.00127	CcSEcCtD
Celecoxib—Nasopharyngitis—Doxorubicin—liver cancer	0.000138	0.00127	CcSEcCtD
Celecoxib—Pancytopenia—Epirubicin—liver cancer	0.000137	0.00126	CcSEcCtD
Celecoxib—Gastritis—Doxorubicin—liver cancer	0.000136	0.00125	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000136	0.00125	CcSEcCtD
Celecoxib—Dysuria—Epirubicin—liver cancer	0.000135	0.00124	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Epirubicin—liver cancer	0.000134	0.00123	CcSEcCtD
Celecoxib—Dysphagia—Doxorubicin—liver cancer	0.000133	0.00122	CcSEcCtD
Celecoxib—Pollakiuria—Epirubicin—liver cancer	0.000133	0.00122	CcSEcCtD
Celecoxib—Eosinophilia—Doxorubicin—liver cancer	0.000132	0.00121	CcSEcCtD
Celecoxib—Nausea—Sorafenib—liver cancer	0.000132	0.00121	CcSEcCtD
Celecoxib—Photosensitivity reaction—Epirubicin—liver cancer	0.000131	0.00121	CcSEcCtD
Celecoxib—Weight increased—Epirubicin—liver cancer	0.000131	0.0012	CcSEcCtD
Celecoxib—Pancreatitis—Doxorubicin—liver cancer	0.000131	0.0012	CcSEcCtD
Celecoxib—Hyperglycaemia—Epirubicin—liver cancer	0.00013	0.00119	CcSEcCtD
Celecoxib—Angina pectoris—Doxorubicin—liver cancer	0.00013	0.00119	CcSEcCtD
Celecoxib—Pneumonia—Epirubicin—liver cancer	0.000129	0.00119	CcSEcCtD
Celecoxib—Infestation—Epirubicin—liver cancer	0.000128	0.00118	CcSEcCtD
Celecoxib—Infestation NOS—Epirubicin—liver cancer	0.000128	0.00118	CcSEcCtD
Celecoxib—Bronchitis—Doxorubicin—liver cancer	0.000128	0.00118	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000127	0.00117	CcSEcCtD
Celecoxib—Pancytopenia—Doxorubicin—liver cancer	0.000126	0.00116	CcSEcCtD
Celecoxib—Neuropathy peripheral—Epirubicin—liver cancer	0.000126	0.00116	CcSEcCtD
Celecoxib—Jaundice—Epirubicin—liver cancer	0.000125	0.00115	CcSEcCtD
Celecoxib—Stomatitis—Epirubicin—liver cancer	0.000125	0.00115	CcSEcCtD
Celecoxib—Urinary tract infection—Epirubicin—liver cancer	0.000125	0.00115	CcSEcCtD
Celecoxib—Conjunctivitis—Epirubicin—liver cancer	0.000125	0.00115	CcSEcCtD
Celecoxib—Dysuria—Doxorubicin—liver cancer	0.000125	0.00115	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000124	0.00114	CcSEcCtD
Celecoxib—Pollakiuria—Doxorubicin—liver cancer	0.000123	0.00113	CcSEcCtD
Celecoxib—Haematuria—Epirubicin—liver cancer	0.000122	0.00113	CcSEcCtD
Celecoxib—Photosensitivity reaction—Doxorubicin—liver cancer	0.000122	0.00112	CcSEcCtD
Celecoxib—Hepatobiliary disease—Epirubicin—liver cancer	0.000121	0.00112	CcSEcCtD
Celecoxib—Weight increased—Doxorubicin—liver cancer	0.000121	0.00111	CcSEcCtD
Celecoxib—Epistaxis—Epirubicin—liver cancer	0.000121	0.00111	CcSEcCtD
Celecoxib—Sinusitis—Epirubicin—liver cancer	0.00012	0.00111	CcSEcCtD
Celecoxib—Hyperglycaemia—Doxorubicin—liver cancer	0.00012	0.0011	CcSEcCtD
Celecoxib—Agranulocytosis—Epirubicin—liver cancer	0.00012	0.0011	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—liver cancer	0.000119	0.0011	CcSEcCtD
Celecoxib—Infestation NOS—Doxorubicin—liver cancer	0.000119	0.00109	CcSEcCtD
Celecoxib—Infestation—Doxorubicin—liver cancer	0.000119	0.00109	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000118	0.00108	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—liver cancer	0.000116	0.00107	CcSEcCtD
Celecoxib—Haemoglobin—Epirubicin—liver cancer	0.000116	0.00106	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—liver cancer	0.000116	0.00106	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—liver cancer	0.000116	0.00106	CcSEcCtD
Celecoxib—Rhinitis—Epirubicin—liver cancer	0.000116	0.00106	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—liver cancer	0.000115	0.00106	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—liver cancer	0.000115	0.00106	CcSEcCtD
Celecoxib—Haemorrhage—Epirubicin—liver cancer	0.000115	0.00106	CcSEcCtD
Celecoxib—Hepatitis—Epirubicin—liver cancer	0.000115	0.00106	CcSEcCtD
Celecoxib—Hypoaesthesia—Epirubicin—liver cancer	0.000115	0.00105	CcSEcCtD
Celecoxib—Pharyngitis—Epirubicin—liver cancer	0.000114	0.00105	CcSEcCtD
Celecoxib—Urinary tract disorder—Epirubicin—liver cancer	0.000114	0.00105	CcSEcCtD
Celecoxib—Oedema peripheral—Epirubicin—liver cancer	0.000114	0.00104	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—liver cancer	0.000113	0.00104	CcSEcCtD
Celecoxib—Connective tissue disorder—Epirubicin—liver cancer	0.000113	0.00104	CcSEcCtD
Celecoxib—Urethral disorder—Epirubicin—liver cancer	0.000113	0.00104	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—liver cancer	0.000112	0.00103	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—liver cancer	0.000112	0.00103	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—liver cancer	0.000111	0.00102	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—liver cancer	0.000111	0.00102	CcSEcCtD
Celecoxib—Erythema multiforme—Epirubicin—liver cancer	0.000109	0.001	CcSEcCtD
Celecoxib—Eye disorder—Epirubicin—liver cancer	0.000108	0.00099	CcSEcCtD
Celecoxib—Tinnitus—Epirubicin—liver cancer	0.000107	0.000988	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—liver cancer	0.000107	0.000985	CcSEcCtD
Celecoxib—Flushing—Epirubicin—liver cancer	0.000107	0.000983	CcSEcCtD
Celecoxib—Cardiac disorder—Epirubicin—liver cancer	0.000107	0.000983	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—liver cancer	0.000107	0.000983	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—liver cancer	0.000107	0.00098	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—liver cancer	0.000107	0.00098	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—liver cancer	0.000106	0.000975	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—liver cancer	0.000106	0.000973	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—liver cancer	0.000105	0.000968	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—liver cancer	0.000105	0.000966	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—liver cancer	0.000105	0.000963	CcSEcCtD
Celecoxib—Angiopathy—Epirubicin—liver cancer	0.000105	0.000961	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—liver cancer	0.000105	0.000961	CcSEcCtD
Celecoxib—Immune system disorder—Epirubicin—liver cancer	0.000104	0.000957	CcSEcCtD
Celecoxib—Mediastinal disorder—Epirubicin—liver cancer	0.000104	0.000955	CcSEcCtD
Celecoxib—Arrhythmia—Epirubicin—liver cancer	0.000103	0.000946	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—liver cancer	0.000102	0.000936	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—liver cancer	0.000101	0.000928	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—liver cancer	0.000101	0.000927	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—liver cancer	9.96e-05	0.000916	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—liver cancer	9.94e-05	0.000914	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—liver cancer	9.89e-05	0.00091	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—liver cancer	9.89e-05	0.00091	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—liver cancer	9.88e-05	0.000909	CcSEcCtD
Celecoxib—Tension—Epirubicin—liver cancer	9.84e-05	0.000905	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—liver cancer	9.82e-05	0.000903	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—liver cancer	9.74e-05	0.000896	CcSEcCtD
Celecoxib—Back pain—Epirubicin—liver cancer	9.7e-05	0.000892	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—liver cancer	9.67e-05	0.000889	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—liver cancer	9.64e-05	0.000887	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—liver cancer	9.63e-05	0.000885	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—liver cancer	9.61e-05	0.000883	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—liver cancer	9.52e-05	0.000876	CcSEcCtD
Celecoxib—Vision blurred—Epirubicin—liver cancer	9.45e-05	0.000869	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—liver cancer	9.42e-05	0.000866	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—liver cancer	9.34e-05	0.000859	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—liver cancer	9.27e-05	0.000852	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—liver cancer	9.14e-05	0.000841	CcSEcCtD
Celecoxib—Tension—Doxorubicin—liver cancer	9.11e-05	0.000837	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—liver cancer	9.09e-05	0.000836	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—liver cancer	9.01e-05	0.000829	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—liver cancer	9.01e-05	0.000828	CcSEcCtD
Celecoxib—Syncope—Epirubicin—liver cancer	8.99e-05	0.000827	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—liver cancer	8.98e-05	0.000825	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—liver cancer	8.98e-05	0.000825	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—liver cancer	8.92e-05	0.00082	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—liver cancer	8.86e-05	0.000815	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—liver cancer	8.82e-05	0.00081	CcSEcCtD
Celecoxib—Cough—Epirubicin—liver cancer	8.75e-05	0.000805	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—liver cancer	8.75e-05	0.000804	CcSEcCtD
Celecoxib—Hypertension—Epirubicin—liver cancer	8.66e-05	0.000796	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—liver cancer	8.58e-05	0.000789	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—liver cancer	8.54e-05	0.000785	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—liver cancer	8.54e-05	0.000785	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—liver cancer	8.54e-05	0.000785	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—liver cancer	8.51e-05	0.000782	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	8.48e-05	0.00078	CcSEcCtD
Celecoxib—Dry mouth—Epirubicin—liver cancer	8.35e-05	0.000768	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—liver cancer	8.34e-05	0.000767	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—liver cancer	8.32e-05	0.000765	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—liver cancer	8.31e-05	0.000764	CcSEcCtD
Celecoxib—Confusional state—Epirubicin—liver cancer	8.25e-05	0.000759	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—liver cancer	8.2e-05	0.000754	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—liver cancer	8.19e-05	0.000753	CcSEcCtD
Celecoxib—Oedema—Epirubicin—liver cancer	8.19e-05	0.000753	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—liver cancer	8.16e-05	0.00075	CcSEcCtD
Celecoxib—Infection—Epirubicin—liver cancer	8.13e-05	0.000748	CcSEcCtD
Celecoxib—Cough—Doxorubicin—liver cancer	8.1e-05	0.000745	CcSEcCtD
Celecoxib—Shock—Epirubicin—liver cancer	8.05e-05	0.00074	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—liver cancer	8.03e-05	0.000738	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—liver cancer	8.01e-05	0.000737	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—liver cancer	8.01e-05	0.000737	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—liver cancer	7.99e-05	0.000734	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—liver cancer	7.95e-05	0.000731	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—liver cancer	7.91e-05	0.000728	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—liver cancer	7.9e-05	0.000726	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—liver cancer	7.9e-05	0.000726	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—liver cancer	7.9e-05	0.000726	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—liver cancer	7.87e-05	0.000724	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	7.85e-05	0.000721	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—liver cancer	7.8e-05	0.000717	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—liver cancer	7.73e-05	0.00071	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—liver cancer	7.64e-05	0.000702	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—liver cancer	7.57e-05	0.000696	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—liver cancer	7.57e-05	0.000696	CcSEcCtD
Celecoxib—Infection—Doxorubicin—liver cancer	7.52e-05	0.000692	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—liver cancer	7.46e-05	0.000686	CcSEcCtD
Celecoxib—Shock—Doxorubicin—liver cancer	7.45e-05	0.000685	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—liver cancer	7.43e-05	0.000683	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—liver cancer	7.42e-05	0.000682	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—liver cancer	7.4e-05	0.000681	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—liver cancer	7.39e-05	0.00068	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—liver cancer	7.36e-05	0.000676	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—liver cancer	7.35e-05	0.000676	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—liver cancer	7.32e-05	0.000673	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—liver cancer	7.3e-05	0.000671	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—liver cancer	7.28e-05	0.000669	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—liver cancer	7.22e-05	0.000664	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—liver cancer	7.21e-05	0.000662	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—liver cancer	7.12e-05	0.000654	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—liver cancer	7.07e-05	0.00065	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—liver cancer	7.06e-05	0.000649	CcSEcCtD
Celecoxib—Constipation—Epirubicin—liver cancer	7e-05	0.000644	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—liver cancer	6.9e-05	0.000634	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—liver cancer	6.85e-05	0.00063	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—liver cancer	6.8e-05	0.000625	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—liver cancer	6.75e-05	0.000621	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—liver cancer	6.75e-05	0.00062	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—liver cancer	6.73e-05	0.000619	CcSEcCtD
Celecoxib—Gastrointestinal pain—Epirubicin—liver cancer	6.69e-05	0.000615	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—liver cancer	6.67e-05	0.000613	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—liver cancer	6.58e-05	0.000605	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—liver cancer	6.54e-05	0.000601	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—liver cancer	6.53e-05	0.0006	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—liver cancer	6.5e-05	0.000598	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—liver cancer	6.48e-05	0.000595	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—liver cancer	6.47e-05	0.000595	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—liver cancer	6.47e-05	0.000595	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—liver cancer	6.24e-05	0.000574	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—liver cancer	6.19e-05	0.000569	CcSEcCtD
Celecoxib—Hypersensitivity—Epirubicin—liver cancer	6.03e-05	0.000554	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—liver cancer	6.02e-05	0.000553	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—liver cancer	5.99e-05	0.00055	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—liver cancer	5.99e-05	0.00055	CcSEcCtD
Celecoxib—Asthenia—Epirubicin—liver cancer	5.87e-05	0.00054	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—liver cancer	5.79e-05	0.000532	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—liver cancer	5.6e-05	0.000515	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—liver cancer	5.58e-05	0.000513	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—liver cancer	5.43e-05	0.0005	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—liver cancer	5.41e-05	0.000498	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—liver cancer	5.36e-05	0.000493	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—liver cancer	5.2e-05	0.000478	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—liver cancer	5.18e-05	0.000476	CcSEcCtD
Celecoxib—Rash—Epirubicin—liver cancer	5.16e-05	0.000475	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—liver cancer	5.16e-05	0.000474	CcSEcCtD
Celecoxib—Headache—Epirubicin—liver cancer	5.13e-05	0.000471	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—liver cancer	5.01e-05	0.00046	CcSEcCtD
Celecoxib—Nausea—Epirubicin—liver cancer	4.86e-05	0.000447	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—liver cancer	4.82e-05	0.000443	CcSEcCtD
Celecoxib—Rash—Doxorubicin—liver cancer	4.78e-05	0.000439	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—liver cancer	4.77e-05	0.000439	CcSEcCtD
Celecoxib—Headache—Doxorubicin—liver cancer	4.74e-05	0.000436	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—liver cancer	4.5e-05	0.000414	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—TP53—liver cancer	5.85e-06	4.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CSF2—liver cancer	5.84e-06	4.45e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.82e-06	4.43e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—SERPINE1—liver cancer	5.81e-06	4.43e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALDOB—liver cancer	5.8e-06	4.42e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—liver cancer	5.79e-06	4.41e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—JUN—liver cancer	5.78e-06	4.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.77e-06	4.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—H2AFX—liver cancer	5.76e-06	4.38e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CTNNB1—liver cancer	5.73e-06	4.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—liver cancer	5.7e-06	4.34e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—liver cancer	5.64e-06	4.3e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—AKT1—liver cancer	5.64e-06	4.3e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—liver cancer	5.63e-06	4.29e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—liver cancer	5.62e-06	4.28e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1A—liver cancer	5.6e-06	4.27e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—liver cancer	5.59e-06	4.26e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CRABP1—liver cancer	5.58e-06	4.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYCS—liver cancer	5.57e-06	4.24e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—AKT1—liver cancer	5.56e-06	4.23e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CRABP1—liver cancer	5.53e-06	4.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GGT1—liver cancer	5.47e-06	4.16e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GOT1—liver cancer	5.47e-06	4.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK8—liver cancer	5.47e-06	4.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—IL6—liver cancer	5.46e-06	4.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—AKT1—liver cancer	5.45e-06	4.15e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—liver cancer	5.44e-06	4.14e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL6—liver cancer	5.4e-06	4.11e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.35e-06	4.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—RAF1—liver cancer	5.32e-06	4.06e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PSMA4—liver cancer	5.27e-06	4.01e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PSMD10—liver cancer	5.27e-06	4.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—H2AFX—liver cancer	5.25e-06	4e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—RAF1—liver cancer	5.25e-06	4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—liver cancer	5.21e-06	3.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—liver cancer	5.21e-06	3.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CB—liver cancer	5.2e-06	3.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MTOR—liver cancer	5.2e-06	3.96e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—liver cancer	5.15e-06	3.92e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GOT2—liver cancer	5.12e-06	3.9e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CB—liver cancer	5.12e-06	3.9e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—liver cancer	5.05e-06	3.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—liver cancer	5.03e-06	3.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—liver cancer	5.03e-06	3.83e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—liver cancer	5.03e-06	3.83e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—liver cancer	5e-06	3.81e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—liver cancer	4.99e-06	3.8e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.98e-06	3.8e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—liver cancer	4.98e-06	3.79e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CPT1B—liver cancer	4.95e-06	3.77e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GLUL—liver cancer	4.95e-06	3.77e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	4.95e-06	3.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—liver cancer	4.94e-06	3.76e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTP1—liver cancer	4.91e-06	3.74e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HPGDS—liver cancer	4.88e-06	3.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1B—liver cancer	4.88e-06	3.72e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—HMOX1—liver cancer	4.84e-06	3.69e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HPGDS—liver cancer	4.84e-06	3.68e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—liver cancer	4.82e-06	3.67e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP2E1—liver cancer	4.82e-06	3.67e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—liver cancer	4.82e-06	3.67e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.81e-06	3.66e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NR1H4—liver cancer	4.77e-06	3.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—liver cancer	4.77e-06	3.64e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTHFR—liver cancer	4.76e-06	3.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—liver cancer	4.76e-06	3.63e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—liver cancer	4.75e-06	3.62e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—liver cancer	4.71e-06	3.58e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTA3—liver cancer	4.69e-06	3.57e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.66e-06	3.55e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—liver cancer	4.64e-06	3.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—JUN—liver cancer	4.64e-06	3.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ESR1—liver cancer	4.64e-06	3.53e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—liver cancer	4.63e-06	3.53e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—liver cancer	4.61e-06	3.51e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—liver cancer	4.6e-06	3.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—F2—liver cancer	4.58e-06	3.49e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	4.54e-06	3.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTM1—liver cancer	4.51e-06	3.44e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYCS—liver cancer	4.51e-06	3.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—liver cancer	4.5e-06	3.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—liver cancer	4.44e-06	3.39e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GOT1—liver cancer	4.42e-06	3.37e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GGT1—liver cancer	4.42e-06	3.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK8—liver cancer	4.39e-06	3.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CG—liver cancer	4.39e-06	3.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APC—liver cancer	4.39e-06	3.34e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.38e-06	3.34e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PSMA4—liver cancer	4.35e-06	3.31e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PSMD10—liver cancer	4.35e-06	3.31e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.32e-06	3.29e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PSMA4—liver cancer	4.31e-06	3.28e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PSMD10—liver cancer	4.31e-06	3.28e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTA4—liver cancer	4.29e-06	3.27e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—liver cancer	4.29e-06	3.27e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP1A1—liver cancer	4.28e-06	3.26e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GOT2—liver cancer	4.23e-06	3.22e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GOT2—liver cancer	4.19e-06	3.19e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTA2—liver cancer	4.18e-06	3.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—liver cancer	4.12e-06	3.14e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—liver cancer	4.11e-06	3.13e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—liver cancer	4.06e-06	3.09e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTA1—liver cancer	4.04e-06	3.07e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—liver cancer	4.02e-06	3.06e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APC—liver cancer	4e-06	3.05e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—liver cancer	4e-06	3.05e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NAT2—liver cancer	3.99e-06	3.04e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—MTHFR—liver cancer	3.99e-06	3.04e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP2E1—liver cancer	3.98e-06	3.03e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTP1—liver cancer	3.97e-06	3.03e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP2E1—liver cancer	3.94e-06	3e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—liver cancer	3.94e-06	3e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—liver cancer	3.94e-06	3e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HMOX1—liver cancer	3.92e-06	2.98e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARA—liver cancer	3.91e-06	2.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CD—liver cancer	3.86e-06	2.94e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALDOB—liver cancer	3.83e-06	2.91e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.82e-06	2.91e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—liver cancer	3.81e-06	2.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SERPINE1—liver cancer	3.81e-06	2.9e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—liver cancer	3.76e-06	2.86e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYCS—liver cancer	3.72e-06	2.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—liver cancer	3.71e-06	2.83e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYCS—liver cancer	3.69e-06	2.81e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—liver cancer	3.67e-06	2.8e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GOT1—liver cancer	3.65e-06	2.78e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GGT1—liver cancer	3.65e-06	2.78e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTM1—liver cancer	3.65e-06	2.78e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CRABP1—liver cancer	3.65e-06	2.78e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—liver cancer	3.65e-06	2.78e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GGT1—liver cancer	3.62e-06	2.76e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GOT1—liver cancer	3.62e-06	2.76e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CD—liver cancer	3.52e-06	2.68e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.51e-06	2.68e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—liver cancer	3.49e-06	2.66e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SERPINE1—liver cancer	3.48e-06	2.65e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP1A1—liver cancer	3.46e-06	2.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—liver cancer	3.45e-06	2.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RAF1—liver cancer	3.44e-06	2.62e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—liver cancer	3.4e-06	2.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MTOR—liver cancer	3.36e-06	2.56e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CB—liver cancer	3.36e-06	2.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CG—liver cancer	3.35e-06	2.55e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—liver cancer	3.32e-06	2.53e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTP1—liver cancer	3.28e-06	2.5e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTP1—liver cancer	3.25e-06	2.48e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HMOX1—liver cancer	3.24e-06	2.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—liver cancer	3.23e-06	2.46e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—MTHFR—liver cancer	3.23e-06	2.46e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—liver cancer	3.22e-06	2.45e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HMOX1—liver cancer	3.21e-06	2.44e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HPGDS—liver cancer	3.19e-06	2.43e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—liver cancer	3.17e-06	2.41e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARA—liver cancer	3.17e-06	2.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1B—liver cancer	3.15e-06	2.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RAF1—liver cancer	3.14e-06	2.39e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—liver cancer	3.12e-06	2.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—liver cancer	3.09e-06	2.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—liver cancer	3.09e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CB—liver cancer	3.07e-06	2.34e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTOR—liver cancer	3.07e-06	2.34e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—liver cancer	3.02e-06	2.3e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTM1—liver cancer	3.01e-06	2.3e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—liver cancer	3.01e-06	2.29e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JUN—liver cancer	3e-06	2.29e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTM1—liver cancer	2.99e-06	2.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—liver cancer	2.98e-06	2.27e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CD—liver cancer	2.95e-06	2.24e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—liver cancer	2.93e-06	2.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—liver cancer	2.92e-06	2.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—liver cancer	2.91e-06	2.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALB—liver cancer	2.91e-06	2.22e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—liver cancer	2.89e-06	2.2e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1B—liver cancer	2.88e-06	2.19e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP1A1—liver cancer	2.86e-06	2.18e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.84e-06	2.17e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PSMA4—liver cancer	2.84e-06	2.17e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PSMD10—liver cancer	2.84e-06	2.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK8—liver cancer	2.84e-06	2.16e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP1A1—liver cancer	2.83e-06	2.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—liver cancer	2.81e-06	2.14e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GOT2—liver cancer	2.77e-06	2.11e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—liver cancer	2.72e-06	2.07e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CG—liver cancer	2.71e-06	2.07e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—MTHFR—liver cancer	2.66e-06	2.03e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—liver cancer	2.66e-06	2.02e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—MTHFR—liver cancer	2.64e-06	2.01e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—liver cancer	2.62e-06	2e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—liver cancer	2.62e-06	1.99e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARA—liver cancer	2.61e-06	1.99e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP2E1—liver cancer	2.6e-06	1.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—liver cancer	2.6e-06	1.98e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARA—liver cancer	2.59e-06	1.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—liver cancer	2.59e-06	1.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—liver cancer	2.57e-06	1.96e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CB—liver cancer	2.57e-06	1.96e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—liver cancer	2.55e-06	1.94e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYCS—liver cancer	2.43e-06	1.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—liver cancer	2.41e-06	1.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—liver cancer	2.41e-06	1.83e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GOT1—liver cancer	2.39e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GGT1—liver cancer	2.39e-06	1.82e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CD—liver cancer	2.38e-06	1.82e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—liver cancer	2.37e-06	1.8e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.33e-06	1.77e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CG—liver cancer	2.24e-06	1.71e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—liver cancer	2.23e-06	1.7e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CG—liver cancer	2.22e-06	1.69e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—liver cancer	2.2e-06	1.68e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—liver cancer	2.2e-06	1.67e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—liver cancer	2.16e-06	1.65e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTP1—liver cancer	2.14e-06	1.63e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—liver cancer	2.14e-06	1.63e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HMOX1—liver cancer	2.12e-06	1.61e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CB—liver cancer	2.08e-06	1.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—liver cancer	2.05e-06	1.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—liver cancer	2.03e-06	1.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—liver cancer	1.98e-06	1.51e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTM1—liver cancer	1.97e-06	1.5e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CD—liver cancer	1.97e-06	1.5e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CD—liver cancer	1.95e-06	1.49e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALB—liver cancer	1.94e-06	1.48e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALB—liver cancer	1.93e-06	1.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—liver cancer	1.9e-06	1.44e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—liver cancer	1.87e-06	1.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.87e-06	1.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—liver cancer	1.81e-06	1.38e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MTHFR—liver cancer	1.74e-06	1.33e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—liver cancer	1.73e-06	1.32e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CB—liver cancer	1.72e-06	1.31e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARA—liver cancer	1.71e-06	1.3e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CB—liver cancer	1.7e-06	1.3e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—liver cancer	1.67e-06	1.27e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—liver cancer	1.66e-06	1.26e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—liver cancer	1.57e-06	1.19e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—liver cancer	1.53e-06	1.16e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.46e-06	1.11e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—liver cancer	1.41e-06	1.08e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.29e-06	9.8e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—liver cancer	1.28e-06	9.74e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALB—liver cancer	1.27e-06	9.67e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—liver cancer	1.27e-06	9.65e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CB—liver cancer	1.12e-06	8.54e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—liver cancer	1.05e-06	7.96e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—liver cancer	1.04e-06	7.9e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—liver cancer	1.03e-06	7.88e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—liver cancer	8.54e-07	6.51e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—liver cancer	8.47e-07	6.45e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—liver cancer	6.84e-07	5.21e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—liver cancer	5.58e-07	4.25e-06	CbGpPWpGaD
